Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Govt announces vaccination programme for kids and those above 60 years of age
The award recognizes and supports promising women scientists
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Subscribe To Our Newsletter & Stay Updated
